Market Research Logo

Acromegaly - Pipeline Review, H2 2016

Acromegaly - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Acromegaly - Pipeline Review, H2 2016’, provides an overview of the Acromegaly pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Acromegaly
    • The report reviews pipeline therapeutics for Acromegaly by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Acromegaly therapeutics and enlists all their major and minor projects
    • The report assesses Acromegaly therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Acromegaly
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Acromegaly
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Acromegaly Overview
    Therapeutics Development
    Pipeline Products for Acromegaly - Overview
    Pipeline Products for Acromegaly - Comparative Analysis
    Acromegaly - Therapeutics under Development by Companies
    Acromegaly - Therapeutics under Investigation by Universities/Institutes
    Acromegaly - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Acromegaly - Products under Development by Companies
    Acromegaly - Products under Investigation by Universities/Institutes
    Acromegaly - Companies Involved in Therapeutics Development
    Aegis Therapeutics, LLC
    Amryt Pharma plc
    Antisense Therapeutics Limited
    Chiasma, Inc.
    Crinetics Pharmaceuticals, Inc.
    DexTech Medical AB
    Foresee Pharmaceuticals, LLC
    Glide Pharmaceutical Technologies Limited
    Ionis Pharmaceuticals, Inc.
    Ipsen S.A.
    Italfarmaco S.p.A.
    Midatech Pharma Plc
    Novartis AG
    Peptron, Inc.
    Strongbridge Biopharma plc
    Sun Pharma Advanced Research Company Ltd.
    Acromegaly - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    AP-102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    atesidorsen sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    COR-005 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FP-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IONIS-GHRLRx - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ITF-2984 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    L-779976 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate long acting - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pasireotide ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Somadex - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SXN-101959 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Acromegaly - Dormant Projects
    Acromegaly - Discontinued Products
    Acromegaly - Product Development Milestones
    Featured News & Press Releases
    Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study
    Jul 13, 2016: ATL1103 Patent Update
    Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study
    Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa
    Jun 01, 2016: Antisense provides update on ATL1103 clinical trials
    May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
    May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI
    May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly
    Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
    Apr 18, 2016: Chiasma Provides Update Regarding FDA’s Complete Response Letter for Mycapssa New Drug Application
    Apr 15, 2016: FDA Issues Complete Response Letter for Mycapssa New Drug Application
    Mar 14, 2016: Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly
    Nov 03, 2015: Strongbridge Biopharma Announces Data Presentation at the Society for Endocrinology BES 2015 Conference
    Sep 09, 2015: ATL1103 Higher Dose Study-Dosing Commenced
    Aug 17, 2015: Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Acromegaly, H2 2016
    Number of Products under Development for Acromegaly - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Acromegaly - Pipeline by Aegis Therapeutics, LLC, H2 2016
    Acromegaly - Pipeline by Amryt Pharma plc, H2 2016
    Acromegaly - Pipeline by Antisense Therapeutics Limited, H2 2016
    Acromegaly - Pipeline by Chiasma, Inc., H2 2016
    Acromegaly - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
    Acromegaly - Pipeline by DexTech Medical AB, H2 2016
    Acromegaly - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016
    Acromegaly - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016
    Acromegaly - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
    Acromegaly - Pipeline by Ipsen S.A., H2 2016
    Acromegaly - Pipeline by Italfarmaco S.p.A., H2 2016
    Acromegaly - Pipeline by Midatech Pharma Plc, H2 2016
    Acromegaly - Pipeline by Novartis AG, H2 2016
    Acromegaly - Pipeline by Peptron, Inc., H2 2016
    Acromegaly - Pipeline by Strongbridge Biopharma plc , H2 2016
    Acromegaly - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Acromegaly - Dormant Projects, H2 2016
    Acromegaly - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Acromegaly, H2 2016
    Number of Products under Development for Acromegaly - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report